<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02702115</url>
  </required_header>
  <id_info>
    <org_study_id>SB-318-1502</org_study_id>
    <nct_id>NCT02702115</nct_id>
  </id_info>
  <brief_title>Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I</brief_title>
  <official_title>A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-318, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis I (MPS I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sangamo Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sangamo Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety, tolerability of ascending doses of
      SB-318. SB-318 is an intravenously delivered Zinc Finger Nuclease (ZFN) Therapeutic for
      genome editing. It inserts a correct copy of the α-L-iduronidase (IDUA) gene into the Albumin
      locus in hepatocytes with the goal of lifelong therapeutic production of the IDUA enzyme.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of the study are to provide long term expression of IDUA and improve the
      current clinical outcome of enzyme replacement therapy (ERT) or hematopoietic stem cell
      transplantation (HSCT) therapy in subjects with attenuated MPS I, a recessive lysosomal
      storage disorder that results from mutations in the gene encoding IDUA. SB-318 is a
      therapeutic for ZFN-mediated genome editing which will be delivered by adeno-associated virus
      (AAV)-derived vectors. SB-318 is intended to function by placement of the corrective copy of
      the IDUA transgene into the genome of the subject's own hepatocytes, under the control of the
      highly expressed endogenous albumin locus, and is expected to provide permanent,
      liver-specific expression of iduronidase for the lifetime of an MPS I patient.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 24, 2017</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 36 months after the SB-318 infusion</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in subjects who receive SB-318 as assessed by Common Terminology Criteria for Adverse Events (CTCAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of SB-318 on IDUA activity</measure>
    <time_frame>Up to 36 months after the SB-318 infusion</time_frame>
    <description>Change from baseline clinical laboratory in measurement of IDUA activity measured in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of SB-318 on urine glycosaminoglycans (GAG) levels</measure>
    <time_frame>Up to 36 months after the SB-318 infusion</time_frame>
    <description>Change from baseline in total GAG, DS GAG, and HS GAG (/creatinine ratio) measured in tissues including blood, liver and cerebrospinal fluid (CSF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AAV2/6 clearance in plasma, saliva, urine, stool, and semen</measure>
    <time_frame>Up to 36 months after the SB-318 infusion</time_frame>
    <description>AAV2/6 clearance by measuring vector genomes in plasma, saliva, urine, stool, and semen by PCR.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>MPS I</condition>
  <arm_group>
    <arm_group_label>Cohort 1: SB-318: Starting Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: SB-318 at Next Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: SB-318 at Next Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB-318</intervention_name>
    <description>A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.</description>
    <arm_group_label>Cohort 1: SB-318: Starting Dose</arm_group_label>
    <arm_group_label>Cohort 2: SB-318 at Next Ascending Dose</arm_group_label>
    <arm_group_label>Cohort 3: SB-318 at Next Ascending Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥ 5 years of age

          -  Clinical diagnosis of attenuated MPS I deficiency (Hurler-Scheie, Scheie, or Hurlers
             status post-HSCT)

        Exclusion Criteria:

          -  Known to be unresponsive to ERT

          -  Neutralizing antibodies to AAV 2/6

          -  Serious intercurrent illness or clinically significant organic disease (unless
             secondary to MPS I)

          -  Receiving antiviral therapy for hepatitis B or C, or with active hepatitis B or
             hepatitis C or HIV 1/2

          -  Lack of tolerance to laronidase treatment with significant IARs or occurrence of
             anaphylaxis

          -  Markers of hepatic dysfunction

          -  Creatinine ≥ 1.5 mg/dL

          -  Contraindication to the use of corticosteroids for immunosuppression

          -  Current treatment with systemic (IV or oral) immunomodulatory agent or steroid use
             (topical treatment allowed)

          -  Participation in prior investigational drug or medical device study within the
             previous 3 months

          -  Prior treatment with a gene therapy product

          -  Elevated or abnormal circulating α-fetoprotein (AFP)

          -  Weight &lt;20 kg at Screening Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sangamo Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>February 29, 2016</study_first_submitted>
  <study_first_submitted_qc>March 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2016</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mucopolysaccharidosis I</keyword>
  <keyword>MPS I</keyword>
  <keyword>Hurler-Scheie syndrome</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>Gene Editing</keyword>
  <keyword>Zinc Finger</keyword>
  <keyword>SB-318</keyword>
  <keyword>Rare</keyword>
  <keyword>Genetic</keyword>
  <keyword>DNA</keyword>
  <keyword>Sangamo</keyword>
  <keyword>Genome editing</keyword>
  <keyword>Empowers</keyword>
  <keyword>ZFN</keyword>
  <keyword>Hurler</keyword>
  <keyword>Gene Specific Targeted Insertion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis I</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

